Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Previous participation in Phase 1 Gilead clinical trial~* Diagnosis of idiopathic pulmonary fibrosis~* Females of childbearing potential and non-vasectomized males must agree to use highly effective methods of contraception~* Females must discontinue nursing~* Comply with study requirements~* Have adequate organ function~Key Exclusion Criteria:~* History or evidence of clinically significant disorder, condition or disease that would pose a risk or interfere with the study~* Pregnant or lactating~* Clinically significant heart, hepatic or renal disease~* History of cancer within 5 years of screening~* Infection that is not controlled despite antibiotics or other treatment~* History of bleeding diathesis within the last 6 months of Day 1~* Known history of human immunodeficiency virus, hepatitis B or C~* Concern's for subjects compliance~* Other conditions that might put the subject at high risk for treatment complications or reduce the chance to obtain data required~* Placed on a lung transplant list~* Previous participation in an idiopathic pulmonary fibrosis clinical trial other than for simtuzumab~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simtuzumab (Type: EXPERIMENTAL): Participants will receive simtuzumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).